Effect of noncompetitive proteasome inhibition on bortezomib resistance. - Wikidata - wikimedia - TriplyDB

Effect of noncompetitive proteasome inhibition on bortezomib resistance.

Effect of noncompetitive proteasome inhibition on bortezomib resistance.

http://www.wikidata.org/entity/Q33588424

about

DangER: protein ovERload. Targeting protein degradation to treat myeloma Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness Synthesis and proteasome inhibition of lithocholic acid derivatives The ubiquitin-proteasomal system is critical for multiple myeloma: implications in drug discovery Interplay between Structure and Charge as a Key to Allosteric Modulation of Human 20S Proteasome by the Basic Fragment of HIV-1 Tat Protein Substituted quinolines as noncovalent proteasome inhibitors.Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1.Proteasome allostery as a population shift between interchanging conformers Noncompetitive modulation of the proteasome by imidazoline scaffolds overcomes bortezomib resistance and delays MM tumor growth in vivo.The Ring Finger Protein RNF6 Induces Leukemia Cell Proliferation as a Direct Target of Pre-B-cell Leukemia Homeobox 1 Design, synthesis, and biological evaluation of bone-targeted proteasome inhibitors for multiple myeloma The antiparasitic clioquinol induces apoptosis in leukemia and myeloma cells by inhibiting histone deacetylase activity.Inhibition of the human proteasome by imidazoline scaffolds.Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors.Ring finger protein 6 promotes breast cancer cell proliferation by stabilizing estrogen receptor alpha.Novel proteasome inhibitors to overcome bortezomib resistance.Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects Proteasome inhibitors: an expanding army attacking a unique target.Proteasome inhibitors in acute leukemia.Harnessing proteasome dynamics and allostery in drug design.The future of proteasome inhibitors in relapsed/refractory multiple myeloma.Proteasome inhibitors as experimental therapeutics of autoimmune diseases.Dissecting a role of a charge and conformation of Tat2 peptide in allosteric regulation of 20S proteasome.Molecular mechanisms of acquired proteasome inhibitor resistance.Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.Positioning of proteasome inhibitors in therapy of solid malignancies.Cross Talk in HEK293 Cells Between Nrf2, HIF, and NF-κB Activities upon Challenges with Redox Therapeutics Characterized with Single-Cell Resolution.Cationic porphyrins are tunable gatekeepers of the 20S proteasome.

P2860

Q26825417-4340FF7F-9B2C-49D2-8EB9-DAA77F47E2FD Q28817181-E83C13F5-85E1-46E7-B893-DD5E785FFB48 Q34769338-3E71A253-CF8A-4648-A71E-5514BEA8624C Q35824929-6EE82967-FCF8-443E-A50B-5471DC329065 Q35843506-E136A73C-AAB3-4C1F-BD86-AA4D791D5475 Q35998619-C982AD31-AE2E-45C9-A7E1-70C805F01899 Q36141927-DD235014-1961-4402-9DDF-33EDAABBE73A Q36483667-19E94694-C2AF-4696-90BD-9AEC4488816C Q36691554-77077233-9DC2-445B-B98B-6BA56B8372AC Q36850026-913A40A0-A6BB-4AD9-9AE9-F87E8537519D Q37332098-3EC44FD2-8123-405D-8390-8BA24A11EE3F Q37333839-2432D2BB-CC8F-4CDC-BAAE-AFB767225FB4 Q37351110-CCEBF51D-414A-41FD-B86F-F5B929B644DC Q37377911-293490CD-368F-444D-8D70-6F688535BAAF Q37746250-18CF5679-031E-4EA4-A5FF-48C9FADD57EB Q37878771-33B01AF3-B8E4-45AB-9CF1-AFB66F545F9E Q37948056-321A7326-D4D5-41E6-8A5C-F1416B420B31 Q37979388-F85E533F-D86A-43AB-B645-4E9BF88B30D4 Q38088003-6318F417-A05F-4FC0-B837-1D82E0F0AEAB Q38177328-8FAF16B6-0790-4319-8889-B664DEA76D47 Q38246060-67B7FB43-EFDD-4EA1-9A14-3094DECB59A5 Q38427697-36A7CB0A-DC3F-4998-B804-ED217E9679B6 Q39194017-8FE2FA47-E244-46E9-8913-84D9ABB414EF Q39278628-EADB068F-A3C1-49B0-93F1-C762F065CCCE Q39469395-FA794652-D9F8-405C-8AB8-70F178B5CAD0 Q47353792-E7EF91A4-B42F-47FC-B142-09368ACDAC69 Q50219625-4850EE16-43F4-4D3E-8D55-89B4CEEF515E Q55401911-777B963F-8823-47E9-B772-965B7B4C05ED

P2860

Effect of noncompetitive proteasome inhibition on bortezomib resistance.

http://www.wikidata.org/entity/Q33588424

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Effect of noncompetitive proteasome inhibition on bortezomib resistance.

@ast

Effect of noncompetitive proteasome inhibition on bortezomib resistance.

@en

Effect of noncompetitive proteasome inhibition on bortezomib resistance.

@nl

type

label

Effect of noncompetitive proteasome inhibition on bortezomib resistance.

@ast

Effect of noncompetitive proteasome inhibition on bortezomib resistance.

@en

Effect of noncompetitive proteasome inhibition on bortezomib resistance.

@nl

prefLabel

Effect of noncompetitive proteasome inhibition on bortezomib resistance.

@ast

Effect of noncompetitive proteasome inhibition on bortezomib resistance.

@en

Effect of noncompetitive proteasome inhibition on bortezomib resistance.

@nl

P1433

Q33588424-82A3EF04-25F0-4B7C-B11A-68839C362DC1

P1476

Q33588424-325C2A6E-4031-47AB-8ECA-1B50E99C5829

P2093

Q33588424-1853F685-4009-47C8-A970-F63FB1EBDD07

Q33588424-1AA2EBD7-FB77-4A46-99B6-661E8B286930

Q33588424-1F3F88ED-3103-4418-AB44-D3E799C88242

Q33588424-3677C6A9-034E-4948-8AB8-9AA77D8D0548

Q33588424-467D96FE-6ECA-45F0-9E80-80587570854D

Q33588424-54E07165-093B-4ED8-9D1D-4E8E038C6DEB

Q33588424-5A91696E-47BC-4D1F-BB74-1CE3F087D638

Q33588424-631E3438-3175-4242-AEB4-5B9A792572B9

Q33588424-6C7F8043-F98D-4924-85EA-3E71EBA27AEF

Q33588424-756C74E5-1D3C-4447-9C38-8A29EAC4C080

P2860

Q33588424-03222D46-4D04-45DD-9AE7-F93F6A6D8328

Q33588424-14789E42-FA8D-4713-8BF1-6F21979F4A0C

Q33588424-1F231BA5-797B-42B1-96F8-E32A4675A5C1

Q33588424-20B90062-962C-4254-84A3-3BD460C1F4FE

Q33588424-2F915250-9F66-4FDB-B5B7-1B33DF994825

Q33588424-311C8312-119C-403A-ACCF-11F69182DCB3

Q33588424-33BC296A-DD63-4E05-A627-538A82013240

Q33588424-4B3CBB13-D9CD-4B69-806D-9D3A0413B328

Q33588424-65977EFE-E258-4288-BCA9-51B1945FC5F2

Q33588424-7CF30D68-FA7D-42BE-8A69-E448799CE38A

P304

Q33588424-9CE49653-7EBC-45C4-B974-2539E342B2AC

P31

Q33588424-C937D08C-FBC6-475D-B214-CD67CC5C6291

P356

Q33588424-5655DB5F-A51B-45AF-81FE-C3B47538E2B8

P407

Q33588424-0EEB1218-9023-44D8-97FF-C3EDF726038C

P433

Q33588424-54B88626-5EDF-4546-B226-90F8C1230AFF

P478

Q33588424-DC3E35A1-90DD-4DF0-AA44-7417046F83F4

P50

Q33588424-2285741A-383F-49FD-B66B-B860ACE7FBE6

Q33588424-68352ABE-ADFE-49E5-9870-89CDA93077BD

Q33588424-A51E0907-B121-43CD-8558-DE5FCC3DD2D6

Q33588424-B839E450-7E01-49AF-B430-11BBF3135041

Q33588424-C47E525D-A9D9-4FD9-BA6F-E8EE19FB610B

Q33588424-F7383C0F-A493-47AA-8B3C-4BAE6EB45151

P577

Q33588424-B20C6D4E-0F0E-4178-BC3E-A9D4E528F161

P5875

Q33588424-70574106-4D78-4101-ADC2-DD135D050A39

P698

Q33588424-86A6D1B4-10FD-4132-9F3F-4E3AE32734C7

P356

P1433

Journal of the National Cancer Institute

P1476

Effect of noncompetitive proteasome inhibition on bortezomib resistance.

@en

P2093

Ami Navon

http://www.w3.org/2001/XMLSchema#string

Christine Chen

http://www.w3.org/2001/XMLSchema#string

David R Rose

http://www.w3.org/2001/XMLSchema#string

Emma Guns

http://www.w3.org/2001/XMLSchema#string

Gerrit Jansen

http://www.w3.org/2001/XMLSchema#string

Hans Adomat

http://www.w3.org/2001/XMLSchema#string

Hans Messner

http://www.w3.org/2001/XMLSchema#string

Jacqueline Cloos

http://www.w3.org/2001/XMLSchema#string

Nazir Jamal

http://www.w3.org/2001/XMLSchema#string

Niels E Franke

http://www.w3.org/2001/XMLSchema#string

P2860

Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution

NMRPipe: a multidimensional spectral processing system based on UNIX pipes

Critical role for Fas-associated death domain-like interleukin-1-converting enzyme-like inhibitory protein in anoikis resistance and distant tumor formation

Acquired resistance of human T cells to sulfasalazine: stability of the resistant phenotype and sensitivity to non-related DMARDs

Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFalpha

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Protein degradation and protection against misfolded or damaged proteins

Inhibition of the sodium/potassium ATPase impairs N-glycan expression and function.

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding.

P304

1069-1082

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJQ198

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P50

Robert A. Batey

P577

2010-05-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44632866

http://www.w3.org/2001/XMLSchema#string

P698

20505154

http://www.w3.org/2001/XMLSchema#string